Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:11:20 2023-12-07 am EST Intraday chart for Moderna, Inc. 5-day change 1st Jan Change
79.02 USD -1.96% +1.51% -56.09%
Sales 2023 * 6.49B Sales 2024 * 4.49B Capitalization 30.73B
Net income 2023 * -5.42B Net income 2024 * -2.33B EV / Sales 2023 *
3,90x
Net cash position 2023 * 5.43B Net cash position 2024 * 3.77B EV / Sales 2024 *
6,00x
P/E ratio 2023 *
-5,85x
P/E ratio 2024 *
-13,1x
Employees 3,900
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.63%
1 week+1.30%
Current month+1.30%
1 month+6.86%
3 months-27.36%
6 months-37.34%
Current year-56.18%
More quotes
1 week
74.50
Extreme 74.5
84.12
1 month
67.62
Extreme 67.62
84.12
Current year
62.55
Extreme 62.55
207.51
1 year
62.55
Extreme 62.55
217.25
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 2011
Director of Finance/CFO 46 2022
President 47 2012
Members of the board TitleAgeSince
Director/Board Member 64 2018
Director/Board Member 73 2020
Director/Board Member 66 2019
More insiders
Date Price Change Volume
23-12-07 79.05 -1.92% 1 462 083
23-12-06 80.6 +2.96% 4,404,650
23-12-05 78.28 -1.99% 2,160,072
23-12-04 79.87 +0.05% 3,171,966
23-12-01 79.83 +2.74% 3,958,346

Delayed Quote Nasdaq, December 07, 2023 at 10:44 am EST

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
80.6USD
Average target price
139.76USD
Spread / Average Target
+73.40%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer